360 related articles for article (PubMed ID: 21649792)
1. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder.
Jiang JQ; Lin S; Xu PC; Zheng ZF; Jia JY
Nephrology (Carlton); 2011 Aug; 16(6):588-94. PubMed ID: 21649792
[TBL] [Abstract][Full Text] [Related]
2. Relation between body mass index and bone mineral density among haemodialysis patients with chronic kidney disease.
Castillo RF; de la Rosa RJ
J Ren Care; 2009 Mar; 35 Suppl 1():57-64. PubMed ID: 19222733
[TBL] [Abstract][Full Text] [Related]
3. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Stathakis CP; Diamanti-Kandarakis E; Dimitroulis D; Perrea DN
J Bone Miner Metab; 2008; 26(1):66-72. PubMed ID: 18095066
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral densitometry in patients on hemodialysis: difference between genders and what to measure.
Orlic L; Crncevic Z; Pavlovic D; Zaputovic L
Ren Fail; 2010 Jan; 32(3):300-8. PubMed ID: 20370444
[TBL] [Abstract][Full Text] [Related]
6. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
7. [Double photon absorptiometry in renal osteodystrophy].
Lechleitner P; Dienstl A; Watfah C; Riccabona G; Koenig P; Dittrich P
Wien Klin Wochenschr; 1990 Mar; 102(5):136-40. PubMed ID: 2321380
[TBL] [Abstract][Full Text] [Related]
8. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density and biochemical markers of bone metabolism in predialysis patients with chronic kidney disease.
Fidan N; Inci A; Coban M; Ulman C; Kursat S
J Investig Med; 2016 Apr; 64(4):861-6. PubMed ID: 26969749
[TBL] [Abstract][Full Text] [Related]
10. Using vertebral bone densitometry to determine aortic calcification in patients with chronic kidney disease.
Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
Nephrology (Carlton); 2010 Aug; 15(5):575-83. PubMed ID: 20649879
[TBL] [Abstract][Full Text] [Related]
11. Histomorphometric diagnostics of renal osteopathy in chronic dialysis patients at high risk of cardiovascular disease.
Žamboch K; Krejčí K; Škarda J; Tichý M; Überall I; Skýpalová P; Langová K; Stejskal D; Švesták M; Zahálková J; Ščudla V; Zadražil J
Int Urol Nephrol; 2015 Jul; 47(7):1195-201. PubMed ID: 25931273
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.
Guven S; Gokce I; Cicek N; Yaman A; Vatansever P; Alpay H
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1383-1390. PubMed ID: 33068383
[TBL] [Abstract][Full Text] [Related]
15. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease.
Scialla JJ; Leonard MB; Townsend RR; Appel L; Wolf M; Budoff MJ; Chen J; Lustigova E; Gadegbeku CA; Glenn M; Hanish A; Raj D; Rosas SE; Seliger SL; Weir MR; Parekh RS;
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2612-9. PubMed ID: 21940840
[TBL] [Abstract][Full Text] [Related]
16. Prediction of bone mineral density of lumbar spine, hip, femoral neck and Ward's triangle by forearm bone mineral density.
Trivitayaratana W; Trivitayaratana P; Kongkiatikul S
J Med Assoc Thai; 2001 Mar; 84(3):390-6. PubMed ID: 11460941
[TBL] [Abstract][Full Text] [Related]
17. Increased serum osteoprotegerin in patients with primary adrenal insufficiency receiving conventional hydrocortisone substitution.
Fichna M; Zurawek M; Fichna P; Gryczynska M; Nowak J; Ruchala M
J Physiol Pharmacol; 2012 Dec; 63(6):677-82. PubMed ID: 23388484
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.
Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Domenig C; Zsontsich T; Klaushofer K; Delling G; Oberbauer R
Am J Kidney Dis; 2002 Mar; 39(3):580-6. PubMed ID: 11877577
[TBL] [Abstract][Full Text] [Related]
19. Bone loss in patients with chronic renal disease: prediction with quantitative bone scintigraphy with SPECT.
Israel O; Gips S; Hardoff R; Rudoy J; Frajewicki V; Iosilevsky G; Bettman L; Frenkel A; Hoffman A; Kolodny GM
Radiology; 1995 Sep; 196(3):643-6. PubMed ID: 7644623
[TBL] [Abstract][Full Text] [Related]
20. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
